The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder